Literature DB >> 2531849

Increased dopamine D2 receptor-mediated inhibition of [14C]acetylcholine release in the dorsomedial part of the nucleus accumbens.

V A Russell1, R Allin, M C Lamm, J J Taljaard.   

Abstract

Dopamine (DA) D2 receptor-mediated inhibition of the K+-stimulated release of [14C]acetylcholine (ACh) from prelabeled rat dorsomedial nucleus accumbens slices was found to be 1.7 times greater than that observed in dorsorostral and ventromedial slices. This observation is consistent with the 1.9 fold higher DA D2 receptor density found in the dorsomedial area. In contrast, there were no differences in the DA D2 receptor-mediated effects on [3H]DA release in these areas. In addition, DA D2 receptor-mediated effects on [3H]DA and [14C]ACh release could not be demonstrated in the ventrorostral part of the nucleus accumbens consistent with the fact that DA D2 receptors were barely detectable in this area. The results suggest that cholinergic terminals in the dorsomedial part of the nucleus accumbens are under greater inhibitory DA control than in other areas of the nucleus accumbens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531849     DOI: 10.1007/bf00964818

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  13 in total

1.  Regional distribution of dopamine D1 and D2 receptors in the nucleus accumbens of the rat.

Authors:  R Allin; V Russell; M Lamm; J Taljaard
Journal:  Brain Res       Date:  1989-11-06       Impact factor: 3.252

2.  Lack of effect of chronic desipramine treatment on dopaminergic activity in the nucleus accumbens of the rat.

Authors:  L Reyneke; R Allin; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1989-07       Impact factor: 3.996

3.  Increased intracranial self-stimulation in rats after long-term administration of desipramine.

Authors:  H C Fibiger; A G Phillips
Journal:  Science       Date:  1981-11-06       Impact factor: 47.728

4.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

5.  The pattern of termination of ventral tegmental afferents into nucleus accumbens: an anterograde HRP analysis.

Authors:  R B Chronister; R W Sikes; J Wood; J F DeFrance
Journal:  Neurosci Lett       Date:  1980-05-01       Impact factor: 3.046

6.  Effect of selective noradrenergic denervation on noradrenaline content and [3H]dopamine release in rat nucleus accumbens slices.

Authors:  V A Russell; M C Lamm; R Allin; A S de Villiers; A Searson; J J Taljaard
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

7.  Characterization of the synaptosomal high-affinity uptake of noradrenaline in the nucleus accumbens of rats.

Authors:  L Hetey; B Zimmermann
Journal:  Biomed Biochim Acta       Date:  1986

Review 8.  Dopamine and depression: a review of recent evidence. II. Theoretical approaches.

Authors:  P Willner
Journal:  Brain Res       Date:  1983-12       Impact factor: 3.252

9.  Presynaptic noradrenergic alpha-receptors and modulation of 3H-noradrenaline release from rat brain synaptosomes.

Authors:  C D De Langen; F Hogenboom; A H Mulder
Journal:  Eur J Pharmacol       Date:  1979-11-23       Impact factor: 4.432

10.  Regional distribution of monoamines in the nucleus accumbens of the rat.

Authors:  R Allin; V A Russell; M C Lamm; J J Taljaard
Journal:  Neurochem Res       Date:  1988-10       Impact factor: 3.996

View more
  2 in total

1.  Anatomical differentiation within the nucleus accumbens of the locomotor stimulatory actions of selective dopamine agonists and d-amphetamine.

Authors:  W D Essman; P McGonigle; I Lucki
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Regional distribution of monoamines and dopamine D1- and D2-receptors in the striatum of the rat.

Authors:  V A Russell; R Allin; M C Lamm; J J Taljaard
Journal:  Neurochem Res       Date:  1992-04       Impact factor: 3.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.